Journal
CLINICAL NEUROPHARMACOLOGY
Volume 23, Issue 2, Pages 82-85Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00002826-200003000-00004
Keywords
amantadine; Parkinson's disease; dyskinesia
Categories
Ask authors/readers for more resources
We performed a double-blind, placebo-controlled, crossover study to assess the effect of amantadine versus placebo on levodopa-induced dyskinesias in Parkinson's disease. We found a 24% reduction in the total dyskinesia score after amantadine administration (p = 0.004). This improvement was achievement without any influence on the severity of on period parkinsonism. The results confirm that amantadine reduces levodopa dyskinesias and support the hypothesis that dyskinesias can be reduced by blockade of excitatory pathways in the basal ganglia.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available